valemetostat   Click here for help

GtoPdb Ligand ID: 12282

Synonyms: (R)-OR-S2 [2] | DS-3201 | DS3201 | Ezharmia®
Approved drug
valemetostat is an approved drug (Japan (2022))
Compound class: Synthetic organic
Comment: Valemetostat (DS-3201) is an orally bioavailable, S-adenosylmethionine (SAM)-competitive inhibitor of the histone methyltransferases enhancer of zeste homologue 1 and 2 (EZH1/EZH2) [2] that are responsible for tri-methylation of lysine 27 on histone H3 (H3K27me3) by the polycomb repressive complex 2 (PRC2). H3K27me3 is an epigenetic modification that represses transcription of tumour suppressor and cell differentiation genes). Valemetostat was developed to target cancers with ongogenic defects that are driven by excessive activity of EZH1 and EZH2 [4-5].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 83.66
Molecular weight 487.22
XLogP 5.25
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CN(C1CCC(CC1)[C@@]1(C)Oc2c(O1)c(C)c(cc2Cl)C(=O)NCc1c(C)cc([nH]c1=O)C)C
Isomeric SMILES Cc1cc(c(c(=O)[nH]1)CNC(=O)c1cc(c2c(c1C)O[C@@](O2)(C)C1CCC(CC1)N(C)C)Cl)C
InChI InChI=1S/C26H34ClN3O4/c1-14-11-15(2)29-25(32)20(14)13-28-24(31)19-12-21(27)23-22(16(19)3)33-26(4,34-23)17-7-9-18(10-8-17)30(5)6/h11-12,17-18H,7-10,13H2,1-6H3,(H,28,31)(H,29,32)/t17?,18?,26-/m1/s1
InChI Key SSDRNUPMYCFXGM-ZZHSESOFSA-N
References
1. Dou F, Tian Z, Yang X, Li J, Wang R, Gao J. (2022)
Valemetostat: First approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma.
Drug Discov Ther, 16 (6): 297-299. [PMID:36310058]
2. Honma D, Kanno O, Watanabe J, Kinoshita J, Hirasawa M, Nosaka E, Shiroishi M, Takizawa T, Yasumatsu I, Horiuchi T et al.. (2017)
Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
Cancer Sci, 108 (10): 2069-2078. [PMID:28741798]
3. Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, Kusumoto S, Morishima S, Tsukasaki K, Kawamata T, Ono T et al.. (2023)
An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma.
Blood, 141 (10): 1159-1168. [PMID:36150143]
4. Kim KH, Roberts CW. (2016)
Targeting EZH2 in cancer.
Nat Med, 22 (2): 128-34. [PMID:26845405]
5. Yamagishi M, Hori M, Fujikawa D, Ohsugi T, Honma D, Adachi N, Katano H, Hishima T, Kobayashi S, Nakano K et al.. (2019)
Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.
Cell Rep, 29 (8): 2321-2337.e7. [PMID:31747604]